Yang Y, Ertl H C, Wilson J M
Department of Molecular and Cellular Engineering, University of Pennsylvania Medical Center, Philadelphia.
Immunity. 1994 Aug;1(5):433-42. doi: 10.1016/1074-7613(94)90074-4.
The use of E1-deleted recombinant adenoviruses in gene therapy has consistently been associated with transient gene expression and inflammation due to immune-based destruction of the infected cells. We have used murine models of adenovirus-mediated gene transfer to liver to investigate these immunologic mechanisms. Adoptive transfer experiments, as well as studies involving genetic knockout mice, confirmed the original hypothesis that cell-mediated immunity induced by E1-deleted adenovirus destroyed trans-gene-expressing hepatocytes and defined MHC class I-restricted CD8+ cytolytic lymphocytes as the primary immune effectors for hepatocyte destruction. Responses mediated by CD4+ cells per se were insufficient to mediate destruction of hepatocytes in vivo, despite the activation of virus-specific T helper cells of Th1 subsets. A better understanding of the response of the host to in vivo gene therapy is important in evaluating its usefulness in humans.
在基因治疗中,使用E1缺失的重组腺病毒一直与短暂的基因表达和炎症相关,这是由于受感染细胞基于免疫的破坏。我们利用腺病毒介导的基因转移至肝脏的小鼠模型来研究这些免疫机制。过继转移实验以及涉及基因敲除小鼠的研究证实了最初的假设,即E1缺失腺病毒诱导的细胞介导免疫破坏了表达转基因的肝细胞,并确定MHC I类限制性CD8 + 细胞毒性淋巴细胞是肝细胞破坏的主要免疫效应器。尽管Th1亚群的病毒特异性T辅助细胞被激活,但CD4 + 细胞本身介导的反应不足以在体内介导肝细胞的破坏。更好地了解宿主对体内基因治疗的反应对于评估其在人类中的实用性很重要。